Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Jun;121(7):e20230818.
doi: 10.36660/abc.20230818.

The Effect of Early Administration of Hypertonic Saline Solution İn Acute Decompensated Heart Failure

[Article in Portuguese, English]
Affiliations

The Effect of Early Administration of Hypertonic Saline Solution İn Acute Decompensated Heart Failure

[Article in Portuguese, English]
Tugce Colluoglu et al. Arq Bras Cardiol. 2024 Jun.

Abstract

Background: There was no scientific evidence about the initial treatment of hypertonic saline solution (HSS) in acutely decompensated heart failure (ADHF).

Objectives: This study assessed the impact of using HSS along with a loop diuretic (LD) as the first diuretic treatment for ADHF, focusing on renal function, electrolyte levels, and clinical outcomes.

Methods: In this retrospective case-control study, 171 adult patients (93 females/78 males) with ADHF were included between January 1, 2022, and December 31, 2022. Patients were allocated into two groups: upfront combo HSS+LD and standardized LD. The primary endpoint was worsening renal function (WRF). Hospitalization for HF and all-cause mortality were evaluated during 6 months of follow-up. The significance level adopted in the statistical analysis was 5%.

Results: The groups exhibited similarities in baseline characteristics.A significantly higher diuresis on the 1st day (3975 [3000-5150] vs. 2583 [2000-3250], p=0.001) and natriuresis on the 2nd hour (116.00 [82.75-126.00] vs. 68.50 [54.00-89.75], p=0.001) in the initial upfront combo HSS+LD were found in comparison with the standardized LD.When compared to the standardized LD, the utilization of HSS led to an increase in serum Na+ (137.00 [131.75-140.00] vs. 140.00 [136.00-142.25], p=0.001 for upfront combo HSS, 139.00 [137.00-141.00] vs. 139.00 [136.00-140.00], p=.0470 for standardized LD), while chloride (99.00 [94.00-103.25] vs. 99.00[96.00-103.00], p=0.295), GFR (48.50 [29.75-72.50 vs. 50.00 [35.50-63.50, p=0.616), and creatinine (1.20 [0.90-1.70] vs. 1.20 [1.00-1.50], p=0.218) remained stable in the upfront combo HSS group when compared to standardized LD group (Cl-: 102.00 [99.00-106.00] vs. 98.00 [95.00-103.00], p=0.001, eGFR: 56.00 [41.00-71.00] vs. 55.00 [35.00-71.00], p=0.050, creatinine:1.10 [0.90-1.40] vs. 1.20 [0.90-1.70], p=0.009). Worsening renal function (16.1% vs 35.5%, p=0.007), and length of stay in the hospital (4 days [3-7] vs. 5 days [4-7], p=0.004) were lower in the upfront combo HSS+LD in comparison with the standardized LD. In-hospital mortality, hospitalization for HF, and all-cause mortality were similar between the two groups.

Conclusion: HSS as an initial therapy, when combined with LD, may provide a safe and effective diuresis without impairing renal function in ADHF. Therefore, HSS may lead to a shorter length of stay in the hospital for these patients.

Fundamento: Não houve evidência científica sobre o tratamento inicial com solução salina hipertônica (SSH) na insuficiência cardíaca agudamente descompensada (ICAD).

Objetivos: Este estudo avaliou o impacto do uso de SSH junto com um diurético de alça (DA) como o primeiro tratamento diurético para ICAD, com foco na função renal, níveis de eletrólitos e resultados clínicos.

Métodos: Neste estudo retrospectivo de caso-controle, 171 pacientes adultos (93 mulheres/78 homens) com ICAD foram incluídos entre 1º de janeiro de 2022 e 31 de dezembro de 2022. Os pacientes foram alocados em dois grupos: combinação inicial de SSH+DA e DA padronizada. O desfecho primário foi piora da função renal (PFR). A hospitalização por IC e a mortalidade por todas as causas foram avaliadas durante 6 meses de acompanhamento. O nível de significância adotado na análise estatística foi de 5%.

Resultados: Os grupos exibiram semelhanças nas características basais. Diurese significativamente maior no 1º dia (3975 [3000-5150] vs. 2583 [2000-3250], p=0,001) e natriurese na 2ª hora (116,00 [82,75-126,00] vs. 131,75-140,00] vs. 94,00-103,25] vs. 99,00 [96,00-103,00], p=0,295), TFG (48,50 [29,75-72,50 vs. 50,00[35,50-63,50, p=0,616) e creatinina (1,20 [0,90-1,70] vs. 1,20 [1,00-1,50], p=0,218) permaneceu estável no grupo SSH combinado inicial quando comparado ao grupo DA padronizado (Cl-: 102,00[99,00-106,00] vs. 98,00[95,00-103,00], p=0,001, TFGe: 56,00 [41,00-71,00] vs. 55,00[35,00-71,00], p=0,050, creatinina: 1,10[0,90-1,40] vs. 1,20 [0,90-1,70], p=0,009). A piora da função renal (16,1% vs. 35,5%, p = 0,007) e o tempo de internação hospitalar (4 dias [3-7] vs. 5 dias [4-7], p = 0,004) foram menores na combinação inicial SSH+DA em comparação com o DA padronizado. A mortalidade hospitalar, a hospitalização por IC e a mortalidade por todas as causas foram semelhantes entre os dois grupos.

Conclusão: SSH como terapia inicial, quando combinada com DA, pode proporcionar uma diurese segura e eficaz sem prejudicar a função renal na ICAD. Portanto, a SSH pode levar a um menor tempo de internação hospitalar para esses pacientes.

PubMed Disclaimer

Conflict of interest statement

Potencial conflito de interesse

Não há conflito com o presente artigo

Figures

Figura Central
Figura Central. : O Efeito da Administração Precoce de Solução Salina Hipertônica na Insuficiência Cardíaca Descompensada Aguda
Figura 1
Figura 1. – Fluxograma. &: Em casos de resposta inadequada a diuréticos de alça IV, a dose de diuréticos de alça IV é aumentada duas vezes. *: A hospitalização por insuficiência cardíaca e a mortalidade por todas as causas foram avaliadas nos primeiros 6 meses após a hospitalização índice. TFGe: taxa de filtração glomerular estimada; IV: intravenoso; SSH: solução salina hipertônica; ICA: insuficiência cardíaca agudamente descompensada; DA: diurético de alça; BUN: nitrogênio na urina no sangue; Cr: creatinina; BNP: peptídeo natriurético cerebral; Htc: hematócrito.
Central Illustration
Central Illustration. : The Effect of Early Administration of Hypertonic Saline Solution İn Acute Decompensated Heart Failure
Figure 1
Figure 1. – Flow chart. &: In cases of inadequate response to iv.loop diuretics, the dose of iv.loop diuretics is increased twofold. * Hospitalization for heart failure and all-cause mortality were evaluated in the first 6 months after index hospitalization. eGFR: estimated glomerular filtration rate; IV: intravenous; HSS: hypertonic salin solution; AHF: acutely decompensated heart failure; LD: loop diuretic; BUN: blood urine nitrogen; Cr: creatinine; BNP: brain natriuretic peptide; Htc: hematocrit.

References

    1. Hardin EA, Grodin JL. Diuretic Strategies in Acute Decompensated Heart Failure. Curr Heart Fail Rep. 2017;14(2):127–133. doi: 10.1007/s11897-017-0319-y. - DOI - PubMed
    1. Chioncel O, Mebazaa A, Maggioni AP, Harjola VP, Rosano G, Laroche C, et al. Acute Heart Failure Congestion and Perfusion Status - Impact of the Clinical Classification on In-hospital and Long-term Outcomes; Insights from the ESC-EORP-HFA Heart Failure Long-Term Registry. Eur J Heart Fail. 2019;21(11):1338–1352. doi: 10.1002/ejhf.1492. - DOI - PubMed
    1. Biegus J, Voors AA, Collins SP, Kosiborod MN, Teerlink JR, Angermann CE, et al. Impact of Empagliflozin on Decongestion in Acute Heart Failure: The EMPULSE Trial. Eur Heart J. 2023;44(1):41–50. doi: 10.1093/eurheartj/ehac530. - DOI - PMC - PubMed
    1. Eid PS, Ibrahim DA, Zayan AH, Elrahman MMA, Shehata MAA, Kandil H, et al. Comparative Effects of Furosemide and Other Diuretics in the Treatment of Heart Failure: A Systematic Review and Combined Meta-analysis of Randomized Controlled Trials. Heart Fail Rev. 2021;26(1):127–136. doi: 10.1007/s10741-020-10003-7. - DOI - PubMed
    1. Mordi NA, Mordi IR, Singh JS, McCrimmon RJ, Struthers AD, Lang CC. Renal and Cardiovascular Effects of SGLT2 Inhibition in Combination With Loop Diuretics in Patients With Type 2 Diabetes and Chronic Heart Failure: The RECEDE-CHF Trial. Circulation. 2020;142(18):1713–1724. doi: 10.1161/CIRCULATIONAHA.120.048739. - DOI - PMC - PubMed

MeSH terms

Substances